** Citi upgrades Healius' HLS.AX rating to "neutral" from "sell" on recent share price decline, the sale of co's unit Lumus Imaging and cost base of its pathology segment reflecting its true business as usual costs
** Brokerage trims price target for co to A$1.05 from A$1.5 to reflect Lumus sale in its forecasts
** Citi forecasts HLS to distribute special dividend of 40 Australian cents/share from sale of Lumus
** The Aussie healthcare firm on Friday shared positive outlook for its pathology business, foreacsting strong growth in 2H
** HLS down ~19.9% YTD as of last close, underperforming against a 3.4% gain on the ASX Health Care index .AXHJ
($1 = 1.5319 Australian dollars)
Reporting by Nikita Maria Jino in Bengaluru
https://www.xm.com/au/research/markets/allNews/reuters/citi-ups-australias-healius-to-neutral-rating-sees-special-dividend-on-the-cards-53971924
Citi ups Australia's Healius to 'neutral' rating, sees special dividend on the cards
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
82.5¢ |
Change
-0.025(2.94%) |
Mkt cap ! $599.0M | |||
| Open | High | Low | Value | Volume |
| 84.5¢ | 85.3¢ | 80.5¢ | $3.619M | 4.382M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 121 | 82.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 84.0¢ | 22122 | 3 |
View Market Depth
| Last trade - 16.10pm 05/09/2025 (20 minute delay) ? |
| HLS (ASX) Chart |